Our country is a big country in the production of bpcs, and the production capacity and income of the industry are increasing. In terms of production, the data showed that the 2021 of chemical raw drugs in our country increased to 3,086,000 tons, an increase of 12.87 percent year-on-year. Production in the first half of 2022 has reached 1.71 million tons, or 3.5 million tons for the whole year. On the revenue side, data shows that the total 2021 revenue of China's chemical bulk drug industry has reached 426.5 billion yuan, and the 2023 revenue of China's chemical bulk drug industry is expected to reach 473.6 billion yuan. Baker Pharmaceutical: recently, Baker Pharmaceutical intends to be listed on the science and Technology Innovation Board of the Shanghai Stock Exchange, raising a total amount of 1.42 billion yuan, the funds raised will be used to finance the planned annual production of 650m tablets of monosodium glutamate and 500m tablets of “Cocktail”, the construction of Litteau's navir API production line, the construction of research and development centres, and supplementary operating funds. The company focuses on the research and development, production and sales of chemicals for the treatment of HIV, hepatitis B and antiviral drug. Xintiandi: Xintiandi announced on January 30 that it had received approval from the State Drug Administration of the People's Republic of China on January 28 for the listing of Vildagliptin's raw materials Packing specifications are 5KG/barrel, 10kg/barrel, 25kg/barrel. Vildagliptin, an orally administered DPP-IV inhibitor used to treat type 2 diabetes, was the product of the original company, Novartis, with sales of $1.284 bn in 2018. Ruilian new material: the company announced on February 3, and hairong pharmaceutical recently signed the“Strategic Cooperation Agreement,” The two sides agreed to carry out comprehensive and in-depth cooperation in areas related to process research and production of innovative drugs and high-end generic drug apis. According to the agreement, Ruilianxin, as the core strategic partner of hairong pharmaceutical in the field of bpcs CDMO/CMO, provides the BPCS process research and production services for Hairong Pharmaceutical. Http://www.zyzhan.com/news/detail/87361.html